Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
[
Title
]
Type
Year
Filters:
Author
is
Kessler, Torsten
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
H
Koch R
,
Gelderblom H
,
Haveman L
,
Brichard B
,
Jürgens H
,
Cyprova S
,
van den Berg H
,
Hassenpflug W
,
Raciborska A
,
Ek T
, et al.
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
J Clin Oncol. 2022:JCO2101942.
PubMed
Google Scholar
P
Pohlen M
,
Thoennissen NH
,
Braess J
,
Thudium J
,
Schmid C
,
Kochanek M
,
Kreuzer K-A
,
Lebiedz P
,
Görlich D
,
Gerth HU
, et al.
Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction.
PLoS One. 2016;11(8):e0160871.
PubMed
Google Scholar
Schliemann C
,
Kessler T
,
Berdel AF
,
Hemmerle T
,
Angenendt L
,
Altvater B
,
Rossig C
,
Mikesch J-H
,
Lenz G
,
Schäfers M
, et al.
Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
Br J Haematol. 2021.
PubMed
Google Scholar